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Abstract 
Background: The purpose of this study was to assess stereotactic body radiation therapy 
(SBRT) results and toxicity for stage I non-small cell lung cancer patients with low 
performance status and severe comorbidity.  
Patients and Methods: From September 2008 to April 2010, 36 patients with 38 lesions 
were treated with hypofractionated SBRT. All except one were medically inoperable, had 
low performance status and/or severe cardiovascular and/or cardiopulmonary 
comorbidity. The patients were immobilized in an Elekta stereotactic body frame to 
improve setup accuracy, and four-dimensional CT scans were used for target delineation. 
Fractions of 15 Gy were prescribed to cover the planning target volume, giving a total 
dose of 45 Gy, with 1 fraction every second day. Cone beam CT was applied at each 
fraction to correct for setup errors. The patients were followed with toxicity evaluation 
and radiographic follow-up.  
Results: Median follow-up time was 13.8 months (0–21 months). The local tumor control 
after 12 months was 100%. Four patients developed regional relapse about 12 months 
after SBRT. The 1-year disease-free survival was 83%. The median tumor shrinkage at 1 
year was 22 mm. Three patients experienced systemic relapse after 13 months. One 
patient developed grade 3 chest pain toxicity and 16 patients reported temporary grade 
1 chest pain toxicity. Two patients reported temporary increased dyspnea. No patient 
experienced a reduction of the performance status after SBRT.   
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Conclusion: SBRT is an effective and safe treatment modality for elderly patients with 
early-stage non-small cell lung cancer, having low performance status and severe 
comorbidity. It is possible to achieve high local control rates with good tolerance. 
 
Introduction 
The treatment of choice for patients with early-stage non-small cell lung cancer 
(NSCLC) is surgical resection [1]. The outcome after lobectomy for early-stage NSCLC 
shows satisfying local control rates between 45 and 95% and 5-year survival rates of 50–
80% [2]. The eligibility criteria for lung surgery include good performance status, 
adequate expected lung function after surgery and limited medical comorbidity. For 
medically inoperable patients, conventionally fractionated radiotherapy has traditionally 
been offered. The probability of local tumor control and survival increases with higher 
doses [3], but even at dose levels of 70 Gy, 30–66% isolated local failure has been 
observed, with a higher rate of distant metastases in patients failing to achieve local 
control [4, 5]. In addition, conventional three-dimensional conformal radiotherapy can 
cause serious side effects, including radiation-induced pneumonitis which is reported in 
14–30% of patients [6, 7]. Due to the fact that many patients with NSCLC have smoking-
related marginal lung function and cardiovascular diseases, these side effects become 
clinically highly relevant. 
Stereotactic body radiation therapy (SBRT) is a treatment modality which allows 
delivery of higher doses to the tumor without increasing doses to the surrounding tissue, 
compared to conventional radiation therapy. Hence, the therapeutic ratio is increased, 
which is especially relevant for patients with severe cardiopulmonary comorbidity. This 
approach for early-stage NSCLC in medically inoperable patients or patients refusing 
surgery has been used and evaluated in several studies [8]. SBRT is proposed as the 
treatment-of-choice for patients with medically inoperable stage I NSCLC [9], yet no 
randomized studies have proven its superiority over conventionally fractionated therapy. 
In this study, we retrospectively reviewed our results in patients with early-stage 
NSCLC and accompanying low performance status and severe comorbidity, treated with 
SBRT. 
Patients and Methods 
Patients 
This is a retrospective study including patients treated with SBRT in our institution, as well as 6 
patients participating in the Nordic Stereotactic Precision and Conventional Radiotherapy Evaluation 
(SPACE) study. The eligibility criteria for SBRT included: (1) pathologically confirmed NSCLC, or PET 
positive pulmonary lesion with evidence of growth evaluated by at least 2 consecutive CT scans, (2) 
stage I (T1N0M0 or T2N0M0) or metachronous cancer, (3) tumor size <60 mm in the longest diameter, 
(4) tumors located >20 mm from the main bronchus or the mediastinal structures, (5) Eastern 
Cooperative Oncology Group (ECOG) performance status (PS) 0–4, and (6) medically unfit for surgery 
or refusal of surgery by the patient.   
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The pretreatment evaluation included complete history and physical examination, baseline 
assessment of respiratory function, chest X-ray and computed tomography (CT) of the chest. PET/CT 
scan was mandatory in the absence of a histological diagnosis.  
Radiation Therapy 
All patients were immobilized using a stereotactic body frame (SBF) (Elekta AB, Stockholm, 
Sweden). Respiration-related mobility was controlled by fluoroscopy and if tumor movement was more 
than 10 mm in the longitudinal direction, diaphragm control was applied to the SBF to reduce 
respiratory movements. Four-dimensional (4D) CT scans (GE Healthcare, Bucks, UK) were used to 
visualize the time dependence of the geometrical positions of the target volumes and organs at risk. The 
4D CT only covered the area around the patient’s tumor, while a full regular CT scan was applied for 
dose planning. Based on the time-dependent information of the 4D CT, a maximum-intensity 
projection CT image series was created and the gross tumor volume (GTV), also accounting for tumor 
movements, was outlined based on these images (center –300; width 1,000). The GTV was expanded by 
5 mm in all directions to create the clinical target volume, which includes microscopic disease. Finally, 
setup margins of 5 mm in all directions were added to create the planning target volume (PTV). 
SBRT dose planning was performed by using collapsed cone algorithm based on the results obtained 
by Lax et al. [10]. The dose was prescribed to the minimum of the PTV, with a total dose of 45 Gy in 3 
fractions, and the 100% isodose line covered the PTV resulting in a homogenous dose distribution. The 
treatment was given every second day. Due to patient conditions and doses to risk organs, some patients 
received dose plans deviating from what is described. Heart, esophagus (defined as 5 cm above and 
below the target), spinal cord (defined as 6 mm above and below the target), the nearest rib to the high-
dose area and the remaining lung volume (total lung minus PTV) were defined as organs at risk. 
The patients were treated using an Elekta Synergy (Elekta AB) linear accelerator, and X-ray volume 
imaging/cone beam CT was used at each fraction to correct for setup errors. Treatment times were 
approximately 40 min per fraction, including immobilization, positioning, imaging and repositioning. 
No significant intrafractional displacement of the target volume was observed as determined by X-ray 
volume imaging. 
Follow-Up 
Response assessment and toxicity evaluation were performed at 6, 12 and 24 weeks after SBRT, and 
then in 6 months intervals. The follow-up included physical examination and chest CT at each visit, and 
PET/CT twice a year. The initial tumor response was evaluated by chest CT according to the RECIST 
criteria. Metabolic response was measured by PET/CT. Toxicity was scored by the National Cancer 
Institute-Common Toxicity Criteria (NCI-CTC) version 3.0. Performance status, dyspnea, coughing, 
esophagitis, chest pain, radiation pneumonitis, emesis, fever, skin erythema, and fatigue were registered. 
Statistical Methods 
Local failure was defined as progressive CT scan abnormalities and/or incremental increases in 
standardized uptake values (SUVs) on PET imaging. Overall survival was defined as time from 
treatment start until death or last patient contact. The survival probabilities were calculated using the 
Kaplan-Meier method. The Fisher exact test was used to evaluate statistical differences between patient 
groups. A p value <0.05 was considered statistically significant.  
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Results 
Patient Characteristics 
Between September 2008 and April 2010, 36 patients with 38 primary lung cancer 
lesions were treated with SBRT in our institute. The characteristics of the patients are 
summarized in table 1.  
The patient’s median age was 74 years (range, 54–85 years). Twenty-six patients (72%) 
were classified as ECOG PS ≥2 at the point of treatment.  
The majority of the patients had a heavy smoking history with a median of 34.4 pack 
years (range, 0–61 pack years).  
Thirty-two patients (82%) had a diagnosis of severe cardiovascular comorbidity, such 
as previous cardiac infarction, coronary heart disease, severe peripheral vascular disease, 
history of stroke or intracranial hemorrhage or aneurysm. Thirty-two patients (88%) had 
chronic lung disease with a significantly reduced lung function. The median FEV1 of all 
patients was 1.4 liter (range, 0.4–4.5 liter), and the FEV1/forced vital capacity ratio was 
45.5% (range, 27–91%). Twenty-two patients (61%) had a diagnosis of Global Initiative 
for Obstructive Lung Disease (GOLD) grade 3 or worse chronic obstructive pulmonary 
disease. Three patients were dependent on continuous oxygen therapy, and 28 patients 
(77%) had dyspnea grade 3–4. 
All 38 cases were discussed at a multidisciplinary tumor board and all but one were 
found to be technically operable. All patients, except one who refused surgery, were 
declared medically inoperable.  
Histological evaluation was performed in 28 lesions (73%; table 1). In 10 cases (26%), 
no histological diagnosis was available due to an unacceptable high risk for pulmonary 
failure related to pneumothorax following thoracocentesis. The 2 lesions identified in 2 
patients were histologically verified as 2 primary tumors.  
All patients without histological diagnosis showed an increasing lung mass on serial 
follow-up chest CT scans, along with high FDG uptake (SUV >3.2) on PET/CT prior to 
treatment. 
The median pretreatment tumor size was 27 mm (range, 11–59 mm) and 18 tumors 
(47%) were >30 mm. In 31 cases (81.5%), we had pretreatment PET/CT, and the median 
SUV was 5.9 (range, 0.9–22.6) in the tumor. 
Radiation Treatment Parameters 
Thirty-six tumors (95%) were treated with 45 Gy in 3 fractions. One patient received 
30 Gy in 3 fractions, limited by the spinal cord dose. Another patient developed a 
bacterial pneumonia, and further treatment had to be aborted after 2 fractions of 15 Gy. 
Two patients were treated with SBRT for bilateral metachronous lung carcinomas, and 1 
patient received SBRT for lung cancer on one side and conventional radiotherapy with 66 
Gy delivered in 2-Gy fractions on the other side, due to hilar localization of this tumor.  
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Diaphragmal control by abdominal compression was used in 12 treated tumors (31%). 
Median craniocaudal respiratory motion of the tumor at CT simulation was 5.1 mm 
(range, 1–13 mm).  
The median GTV volume was 7.26 cm
3 (range, 0.6–57 cm
3) with a corresponding PTV 
volume of 50.6 cm
3 (range, 11.1–171 cm
3). The median and maximum doses to PTV were 
129.4% (range, 118.8–147.1%) and 152.3% (range, 147–189%), respectively. A conformity 
index (V100%/VPTV) of <1.4 was intended in all cases.  
The median dose exposure to the heart was 0.27 Gy (range, 0.07–6.5 Gy). The 
maximum dose to the esophagus and the spinal cord was median 10.7 Gy (range, 0.8–40 
Gy) and 8.4 Gy (range, 0.8–20.8 Gy), respectively. The part of the total lung volume 
minus PTV receiving 10 Gy or more (V10) was median 11.7% (range, 5.4–33.2%). The 
median dose per fraction to 2 cm
3 of the ribs was 12.1 Gy (range, 0.2–24.3 Gy). 
Local Tumor Control and Survival 
The follow-up data included clinical and radiographic results from 36 patients treated 
for 38 pulmonary lesions. All results are summarized in table 2. The median follow-up 
time was 13.8 months (range, 0–21 months). At the time of analysis, all except 1 patient 
were alive. The local control rate was 100% after 1.5 years. The disease-free survival was 
89% (24/27) and 83% (20/24), at 6 and 12 months, respectively. Four patients (11%) 
developed metastasis in the mediastinal lymph nodes at an average of 1.5 years after 
SBRT. In 3 patients, we diagnosed distant failure: 2 patients had developed liver 
metastasis 15 months after SBRT, and 1 patient developed brain metastasis and died 6 
months after SBRT. The median tumor shrinkage after 6 and 12 months was 17 mm 
(range, 5–38 mm) and 22 mm (4–59 mm), respectively. The reduction of the metabolic 
activity measured by SUV in PET/CT 12 months after SBRT was 7.95 (range, 1.2–22.6).  
Toxicity 
None of the patients reported aggravation of coughing, esophagitis, emesis, fever or 
fatigue, and we did not observe any case of radiation-induced rib fracture.  
The observed performance status of the patients was stable throughout the observation 
period, except the variations following exacerbating chronic obstructive pulmonary 
disease. 
Follow-up CT’s detected pneumonitis grade 1 in 34 cases (89%) according to CTC3.0, 
1 patient with grade 2 pneumonitis, initiating 6 weeks after SBRT, and 1 patient 
experiencing a period with grade 3 pneumonitis. Only 2 patients (5%) reported temporary 
increased dyspnea. Three patients reported subjective respiratory improvement after 
SBRT.  
Sixteen patients (44%) reported temporary chest pain, related to the radiation field. All 
patients except one classified the pain as grade 1, and after 1 year only 3 patients (8%) had 
chest discomfort once in a while. There was no significant association between chest pain 
and given dose to the ribs (p = 0.683). One patient presented with thoracic pain, dyspnea, 
chest wall edema with a distinct bulge and severe erythema over the right chest wall,  
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already 4 weeks after SBRT. The CT scan showed significant tumor reduction, 
consolidating lung parenchyma and atelectasis due to stricture of a segment bronchus and 
a pronounced thoracic edema. The solid swelling over the right chest wall was 
histologically confirmed as inflammatory tissue without evidence of atypical cells. After 3 
months of treatment with corticosteroids, NSAID, and morphine, the clinical and 
radiological alterations reversed and medication could be reduced.  
Discussion 
This study shows promising results after SBRT for early-stage NSCLC with a local 
control rate of 100% after 18 months and a 1-year disease-free survival of 83% in a cohort 
of elderly patients with a high degree of comorbidities. It has been previously shown that 
SBRT in early-stage NSCLC results in excellent local control rates that are equal to 
surgery with a minimal toxicity [11, 12]. Surgery alone may result in a 5-year survival of 
60–80% in stage I and about 30–40% in stage II [13]. Kelsey et al. published an extensive 
series of 975 patients operated for stage I NSCLC [14]. They reported a 5-year local 
recurrence rate of 23%, with a median time to recurrence of 14 months. The 5-year risk of 
treatment failure was 42%, including local and/or distant relapses [14]. SBRTs for stage I 
NSCLC with doses between 18 and 75 Gy have shown a 2-year survival between 64 and 
79% and local control rates between 80 and 100% [15–17]. 
Three-dimensional conformal radiotherapy with doses up to 70 Gy is less effective 
than surgery and many patients experience local recurrence [18, 19].  
Both dose escalation and reduction of treatment time have great impact on survival as 
shown in the CHART trial [15, 20]. SBRT allows both increasing the total biological dose 
dramatically and reducing overall treatment time. In our study, the total dose was 
delivered in only 5 days. If we calculate the biologic effect of 45 Gy (periphery dose) 
delivered in 3 fractions, converted into standard fractions of 2 Gy (EQD2) and taking α/β 
values of 10 for tumor and 3 for normal tissue effects, the result is equivalent to total 
doses of 94 and 162 Gy, respectively. However, the use of the LQ model in such extremely 
hypofractionated treatment schedules is questionable.  
In our material, the median age was 74 years at the time of treatment. Moreover, over 
70% of our patients had a poor performance status (ECOG PS ≥2), which may reflect the 
future patient population. Haasbeek et al. have recently published data on a group of 
elderly patients with early-stage NSCLC and excessive cardiopulmonary comorbidity, 
treated with SBRT with a local control rate of 89% after 3 years and a 1- and 3-year 
survival rate of 86 and 45%, respectively [21].  
Radiological changes in the lung parenchyma, suggesting acute pneumonitis or fibrosis 
are commonly seen after SBRT, but usually without clinical relevance [22]. In our 
material, only 4 patients had no clinical or radiographic sign of radiation-induced 
pneumonitis and after 1 year, 66% of our patients still had typical radiographic patterns 
visible on their chest CT scans, mostly asymptomatic. The radiological changes were 
transient, and decreased over time. Only 2 patients experienced increased dyspnea after 
SBRT. Even the patients dependent on continuous oxygen therapy tolerated the treatment 
excellently. Unfortunately, we do not have data from spirometric tests after treatment in  
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all patients. Studies measuring pulmonary function before and after treatment with SBRT 
have not shown permanent declines in measured functions [8]. 
Extrapulmonary toxicity in SBRT is a potential problem, and high-dose contribution 
to mediastinal organs such as esophagus, large airways and large vessels should be 
avoided. Skin erythema, fractures of the ribs, vertebral body, and chest wall inflammation 
with acute or chronic chest pain are side effects that may appear in high-dose areas. For 
chronic chest pain and rib fracture after SBRT, a dose response correlation and a dose 
volume relationship are well documented [23]. Uematsu et al. reported 2 patients 
developing bone fractures in the rib and vertebra within the 80%-isodose prescription line 
[17]. Pettersson et al. found 13 rib fractures in 33 patients after SBRT with 45 Gy in 3 
fractions [24]. The authors suggest that the risk of radiation-induced rib fracture 
following SBRT is related to the dose to 2 cm
3 of the rib. In our population, we saw no 
correlation between dose to the ribs and chest pain incidence. Another group identified 
the volume of the chest wall, receiving >30 Gy as a predictor for acute and chronic chest 
wall pain and rib fracture [25]. In our material, 1 patient with doses exceeding the 
recommended values developed transient thoracic pain, chest wall edema and severe skin 
erythema in the radiation field 4 weeks after SBRT. The minimum distance from the 
lesion to the chest wall was just 25 mm, resulting in a high dose to this region. However, 
chronic chest pain after thoracic surgery is a common problem for up to 10% of patients 
and the response to treatment is poor [26]. 
Even if we lack results from randomized clinical trials comparing SBRT with surgery or 
three-dimensional conformal radiotherapy, the non-invasive character of the procedure, 
the short treatment time with few fractions, the possibility of outpatient treatment and 
nearly no restriction for the patients with medical problems in addition to high local 
control rates and mild toxicity, makes SBRT a highly attractive treatment approach [23]. 
Combination of rising life expectancy, more sophisticated and available diagnostics, 
increasing incidence of lung cancer and advances in management of cardiopulmonary 
diseases will result in a growing group of patients with early-stage NSCLC, not accessible 
for surgery.  
Conclusion 
SBRT with 45 Gy in 3 fractions is a safe and effective treatment for patients with early-
stage NSCLC with low performance status and severe comorbidity. The local control rate 
and disease-free survival after 1 year was 100 and 83%, respectively. Toxicity, even for 
elderly patients with severe comorbidity is acceptable. 
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Table 1. Patient characteristics of 36 patients treated with SBRT for 38 lesions 
Gender, n   
Male  .13 
Female  .23 
Age at treatment, years   
Median  .74 
Range  .54–85 
ECOG PS, n   
0  .03 
1  0.9 
2  .18 
3  .08 
Tumor histology, n   
Adenocarcinoma  .17 
Squamous cell carcinoma  .10 
Large cell carcinoma  .01 
No histology  .10 
Tumor diameter, mm   
Median  .26 
Range  .11–59 
Pretreatment PET, SUV   
Median 6.8 
Range 0.9–22.6 
FEV1 pretreatment, liter   
Median 1.4 
Range 0.4–4.5 
Cardiovascular comorbidity, n  32 
 
 
Table 2. Treatment results of 36 patients treated with SBRT for 38 lesions 
Follow-up, months   
Median     13.8 
Range  00.0–21 
Local control  .038 (100%) 
Disease-free survival after 1 year  0.83% 
Tumor shrinkage after 1 year, mm   
Median  .022 
Range  00.4–59 
Recurrence, n   
In-field  .000 
Regional lymph nodes  00.4 (10.5%) 
Distant  .003 (8%) 
Radiation pneumonitis, n   
Radiographic  0.34 (89.5%) 
Clinical  .002 (5%) 
Chest pain   0.16 (44%) 
Dyspnea  .002 (5%) 
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